Becton Dickinson Stock - Analyst consensus and long-term profile

Edited by ad hoc news Long-Term & Business-Model Desk. Verified prior to publication on 06/20/2026, 10:53 CET. Details in the imprint.

Becton Dickinson (US0718131099) is a global medical technology company best known for its syringes and diagnostic systems. With no new company announcement or major market-moving report in the past day from primary sources, today’s focus shifts to how analysts value the stock and how the long-term business model underpins those views.

How analysts value the stock

Analyst coverage for Becton, Dickinson and Company is broad, reflecting its position in the global medical technology sector. According to consensus data compiled by MarketBeat, most analysts currently rate Becton Dickinson stock in the “Moderate Buy” range, with the majority of recommendations between Hold and Buy.

Recent consensus figures cited by MarketBeat show a blended 12-month price target in the mid- to high-$200s per share, implying upside versus the stock’s last quoted levels in the mid-$140s on the New York Stock Exchange as of 06/18/2026. These targets aggregate views from large investment banks and regional brokers, capturing expectations for steady mid-single-digit revenue growth and gradual margin expansion in coming years.

Long-term business and earnings profile

Becton Dickinson’s long-term profile is shaped by stable demand for single-use medical disposables and growing needs in diagnostics. In its most recent quarterly release for the second fiscal quarter of 2026, the company reported revenue growth in the low- to mid-single-digit percentage range year-on-year, while reiterating its full-year guidance for both sales and adjusted earnings per share.

Management highlighted ongoing investments in higher-margin diagnostic platforms and medication management systems, alongside cost programs designed to offset inflationary pressures in raw materials and labor. These initiatives are intended to sustain earnings growth even in a more normalized post-pandemic environment, where COVID-related tailwinds in testing have faded.

The business behind the stock

Becton, Dickinson and Company describes itself as a global medical technology company that develops, manufactures and sells a broad range of medical supplies, devices, laboratory equipment and diagnostic products. Its operations are organized into three primary segments: BD Medical, BD Life Sciences and BD Interventional.

BD Medical includes needles and syringes, intravenous catheters and insulin delivery systems, serving hospitals, clinics and patients with chronic diseases. BD Life Sciences spans specimen collection systems and diagnostic platforms used in clinical laboratories, while BD Interventional focuses on devices for surgery, urology and oncology, including catheters and vascular access products.

What the company sells

One of Becton Dickinson’s signature product lines is its BD disposable syringe portfolio, which ranges from standard hypodermic syringes to specialized insulin and safety syringes. These products are used worldwide in hospitals, physician practices and home care settings, forming a recurring revenue base given their single-use nature.

Where the stock trades today

The shares of Becton Dickinson (US0718131099) trade on the New York Stock Exchange under the ticker BDX, last quoted at approximately $143.99 as of 06/18/2026, 16:00 Eastern Time.

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.